Back To: Home : Featured Technology : Gene and Cell Therapies

CLICK HERE FOR WHAT'S NEW IN:
 

Tekmira sees promise in TKM-HTG
May 2015
SHARING OPTIONS:

VANCOUVER, British Columbia—The Keystone Symposia Conference: Liver Metabolism and Nonalchoholic Fatty Liver Diseases in March saw Tekmira Pharmaceuticals Corp. share new preclinical data on TKM-HTG, its RNAi therapeutic candidate for the treatment of hypertriglyceridemia. The most important finding resulting from the preclinical studies, as seen in a mouse model fed a high-fat containing diet, is the super-additive effects on plasma triglycerides that result from silencing the apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) genes expressed in the liver. In the human apoC3-Tg mouse model, silencing the apoC3 gene resulted in rapid, potent and sustained plasma triglyceride lowering, and the gene silencing and triglyceride-lowering effects from a single administration lasted for more than two weeks. Encouraging cholesterol profile changes and significant glucose-lowering effects were also seen.

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.